Corporate Banner
Satellite Banner
Technology
Networks
Scientific Communities
 
Become a Member | Sign in
Home>News>This Article
  News
Return

New Approach to Accelerate Dementia Research

Published: Monday, June 23, 2014
Last Updated: Monday, June 23, 2014
Bookmark and Share
The Medical Research Council has launched the UK Dementias Research Platform, a £16 M public-private partnership set up to speed up research into dementias.

The collaboration will study data from 2 million volunteers aged 50 and over who belong to existing population studies – including UK Biobank and the Million Women Study. UK Biobank is part-funded by the Medical Research Council (MRC).

The partnership aims to enable earlier detection, improved treatment and, ultimately, prevention of the disease, by looking not just at what is going wrong in the brain, but at the brain in the context of the whole body.

With the UK Dementias Research Platform (UKDP), the MRC is bringing together industry expertise and investigator teams from eight UK universities and teaming them with what will be the world’s largest group of participants in dementias research.

The Platform’s combination of skills and resources, and its focus on looking at the whole body in order to understand neurodegenerative disease, aims to unearth completely new approaches for intervention, including new drug treatments.

The Platform will investigate the causes of dementia across a range of different neurodegenerative conditions, such as Alzheimer’s, Parkinson’s and motor neurone disease.

Studying the data will give researchers a better understanding of who is at risk of getting dementia, possible triggers that lead to disease, and what might speed up or slow down its progression.

The resource will also allow scientists to identify better biological and cognitive measures (biomarkers) of the key changes associated with dementia. This will enable them to develop new and more accurate clinical trials and find ways to limit and improve symptoms and quality of life for those affected.

Dr John Gallacher, from Cardiff University and director of the UKDP, said: “We now know that neurodegeneration can be linked to changes taking place in parts of the body seemingly unrelated to the brain and many years before dementia is diagnosed. For example, inflammation or infection in a completely different organ may be related to the development of dementia or to accelerating the onset in people with the disease. So it’s imperative that we look at the different stages of disease development: people who are yet to develop dementia; those who are known to be at risk of developing it, and those who are already in the early stages of the disease.

“By looking at the links between development of the disease and other factors – such as diet or illness – we hope to unearth targets for new drugs or new uses for existing drugs.”

The project has attracted industry partners from both within the UK and abroad: Araclon; MedImmune, the global biologics research & development arm of AstraZeneca; GSK; IXICO; Janssen Research & Development in collaboration with Johnson & Johnson Innovation; and SomaLogic. The academic partners are: Cardiff University (academic lead), University of Cambridge, University of Edinburgh, Imperial College London, Newcastle University, University of Oxford, Swansea University and University College London.

Science Minister David Willetts said: “This new £16 million UK Dementia Platform will create the world’s largest ever study group for research into dementia, ensuring that data is freely available to support the work of international scientists in this very important area.

“The collaborative approach demonstrated by the Medical Research Council and its business partners through this platform is critical in helping us to achieve our target of doubling dementia research funding and making the UK the best place in the world to do life sciences.”


Further Information
Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 2,500+ scientific posters on ePosters
  • More Than 3,700+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.


Scientific News
The Changing Tides of the In Vitro Diagnostics Market
With the increasing focus in personalized medicine, diagnostics plays a crucial role in patient monitoring.
Immunotherapy Agent Benefits Patients with Drug-Resistant Multiple Myeloma in First Human Trial
Daratumumab proved generally safe in patients, even at the highest doses.
Low-level Arsenic Exposure Before Birth Associated with Early Puberty in Female Mice
Study examine whether low-dose arsenic exposure could have similar health outcomes in humans.
LaVision BioTec Reports on the Neuro Research on the Human Brain After Trauma
Company reports on the work of Dr Ali Ertürk from the Institute for Stroke and Dementia Research at LMU Munich.
NIH Study Shows No Benefit of Omega-3 Supplements for Cognitive Decline
Research was published in the Journal of the American Medical Association.
Less May Be More in Slowing Cholera Epidemics
Mathematical model shows more cases may be prevented and more lives saved when using one dose of cholera vaccine instead of recommended two doses.
Investigating the Vape
Expert independent review concludes that e-cigarettes have potential to help smokers quit.
NIH Launches Human RSV Study
Study aims to understand infection in healthy adults to aid development of RSV medicines, vaccines.
Researchers Discover Synthesis of a New Nanomaterial
Interdisciplinary team creates biocomposite for first time using physiological conditions.
Poor Survival Rates in Leukemia Linked to Persistent Genetic Mutations
For patients with an often-deadly form of leukemia, new research suggests that lingering cancer-related mutations – detected after initial treatment with chemotherapy – are associated with an increased risk of relapse and poor survival.
Scroll Up
Scroll Down
Skyscraper Banner

Skyscraper Banner
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,500+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
3,700+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FREE!